Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Taïeb J, Sayah L, Heinrich K, Kunzmann V, Boileve A, Cirkel G, Lonardi S, Chibaudel B, Turpin A, Beller T, Hautefeuille V, Vivaldi C, Mazard T, Bauguion L, Niger M, Prager GW, Coutzac C, Benedikt Westphalen C, Auclin E, Pilla L. Taïeb J, et al. Among authors: pilla l. Eur J Cancer. 2023 Jul;188:90-97. doi: 10.1016/j.ejca.2023.04.012. Epub 2023 Apr 23. Eur J Cancer. 2023. PMID: 37229836
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger E, Boccaccino A, Lapeyre-Prost A, Perret A, Gallois C, Antista M, Pilla L, Lecomte T, Scartozzi M, Soularue E, Salvatore L, Bourgeois V, Salati M, Tougeron D, Evesque L, Vaillant JN, El-Khoury R, Lonardi S, Cremolini C, Taieb J. Hafliger E, et al. Among authors: pilla l. Eur J Cancer. 2022 Jun;168:34-40. doi: 10.1016/j.ejca.2022.03.011. Epub 2022 Apr 15. Eur J Cancer. 2022. PMID: 35436675
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A. Bergen ES, et al. Among authors: pilla l. Gastric Cancer. 2023 May;26(3):425-437. doi: 10.1007/s10120-023-01374-5. Epub 2023 Mar 7. Gastric Cancer. 2023. PMID: 36881202
MSI colorectal cancer, all you need to know.
Flecchia C, Zaanan A, Lahlou W, Basile D, Broudin C, Gallois C, Pilla L, Karoui M, Manceau G, Taieb J. Flecchia C, et al. Among authors: pilla l. Clin Res Hepatol Gastroenterol. 2022 Nov;46(9):101983. doi: 10.1016/j.clinre.2022.101983. Epub 2022 Jun 19. Clin Res Hepatol Gastroenterol. 2022. PMID: 35732266 Review.
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L. Filipazzi P, et al. Among authors: pilla l. Clin Cancer Res. 2012 Dec 1;18(23):6485-96. doi: 10.1158/1078-0432.CCR-12-1516. Epub 2012 Oct 2. Clin Cancer Res. 2012. PMID: 23032742 Clinical Trial.
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Huber V, Di Guardo L, Lalli L, Giardiello D, Cova A, Squarcina P, Frati P, Di Giacomo AM, Pilla L, Tazzari M, Camisaschi C, Arienti F, Castelli C, Rodolfo M, Beretta V, Di Nicola M, Maio M, Del Vecchio M, de Braud F, Mariani L, Rivoltini L. Huber V, et al. Among authors: pilla l. J Immunother Cancer. 2021 Feb;9(2):e001167. doi: 10.1136/jitc-2020-001167. J Immunother Cancer. 2021. PMID: 33589521 Free PMC article.
58 results